Larger RCC Tumors Raise Brain Metastasis Risk
Larger tumors and younger age are significantly associated with an increased risk of brain metastasis in patients with renal cell carcinoma, according to investigators.
Kidney Cancer
Acute Kidney Injury Seems to Promote Renal Cell Carcinoma
AKI promotes the development of papillary renal cell carcinoma from single progenitors.
Kidney Failure Related to Urinary Cancers Tied to Worse Outcomes
In a study, patients with kidney failure due to urinary tract cancers had an increased mortality risk and decreased access to kidney transplantation if they had active malignancy at the start of dialysis.
Targeted Assessments May Be Needed for Some Patients With Localized Renal Cell Carcinoma
Assessments and interventions for younger and female patients with RCC may need to be targeted, as these patients may have a greater fear of disease recurrence.
Nivolumab Outperforms Everolimus in Advanced RCC, Study Confirms
In a long-term follow-up of the CheckMate trial, investigators observed consistently prolonged survival with nivolumab compared with everolimus.
Immune Checkpoint Inhibitors for mRCC Safe, Effective in a Real World Setting
In a single-center study of 177 patients with metastatic renal cell carcinoma who received at least a single dose of an immune checkpoint inhibitor, the median time to next treatment was 8.9 months and median overall survival time was 26.7 months.
Preoperative Bone Metastases Not Prognostic in mRCC
Bone metastases less predictive in the setting of cytoreductive nephrectomy.
Metastasectomy Found to Prolong Survival in Selected mRCC Cases
In a study, metastasectomy was associated with significantly longer median progression-free and overall survival in some mRCC patients.
Ipilimumab Plus Nivolumab Effective for mRCC With Brain Metastases
Dual immunotherapy appears to have clinical efficacy beyond the first-line setting in patients with metastatic renal cell carcinoma with brain metastases.
Risky Business: A New Scoring System for Metastatic Renal Cell Carcinoma
The new risk score, developed by Emory researchers, could be a useful tool for determining overall and progression-free survival after immunotherapy.
Next post in Kidney Cancer
